A number of other brokerages have also commented on RDHL. Zacks Investment Research upgraded REDHILL BIOPHAR/S from a hold rating to a buy rating and set a $4.75 price target on the stock in a report on Tuesday, March 17th. HC Wainwright reissued a buy rating and issued a $14.00 target price (down from $18.00) on shares of REDHILL BIOPHAR/S in a research report on Thursday, March 5th. One investment analyst has rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company’s stock. REDHILL BIOPHAR/S has an average rating of Buy and a consensus price target of $14.75.
Shares of REDHILL BIOPHAR/S stock opened at $7.02 on Friday. The business’s fifty day simple moving average is $7.02 and its 200 day simple moving average is $5.95. The firm has a market capitalization of $259.58 million, a P/E ratio of -4.78 and a beta of 1.70. REDHILL BIOPHAR/S has a 12 month low of $3.26 and a 12 month high of $9.12. The company has a current ratio of 5.83, a quick ratio of 5.67 and a debt-to-equity ratio of 1.88.
Several hedge funds and other institutional investors have recently made changes to their positions in RDHL. Gagnon Securities LLC purchased a new position in shares of REDHILL BIOPHAR/S in the fourth quarter valued at $683,000. Ibex Investors LLC grew its position in shares of REDHILL BIOPHAR/S by 5.5% in the first quarter. Ibex Investors LLC now owns 1,850,000 shares of the biotechnology company’s stock valued at $8,380,000 after purchasing an additional 96,605 shares in the last quarter. Phoenix Holdings Ltd. purchased a new position in shares of REDHILL BIOPHAR/S in the first quarter valued at $379,000. State Street Corp purchased a new position in shares of REDHILL BIOPHAR/S in the fourth quarter valued at $484,000. Finally, Sowell Financial Services LLC grew its position in shares of REDHILL BIOPHAR/S by 153.6% in the first quarter. Sowell Financial Services LLC now owns 88,225 shares of the biotechnology company’s stock valued at $400,000 after purchasing an additional 53,435 shares in the last quarter. Institutional investors own 17.62% of the company’s stock.
REDHILL BIOPHAR/S Company Profile
RedHill Biopharma Ltd., a specialty biopharmaceutical company, focuses on the development and commercialization of late clinical-stage drugs for the treatment of gastrointestinal diseases in the United States. It operates through two segments, Commercial Operations and Research & Development. The company's clinical-stage development programs comprise TALICIA, a drug that is in Phase III clinical trial for the helicobacter pylori infection; RHB-104 that is in Phase III clinical trials for crohn's disease, as well as that has completed Phase II clinical trial for multiple sclerosis; RHB-204 for pulmonary nontuberculous mycobacteria infections; BEKINDA 24 mg that has completed Phase III clinical trial for acute gastroenteritis and gastritis; BEKINDA 12 mg that has completed Phase II clinical trial for irritable bowel syndrome with diarrhea; RHB-106 for bowel preparation; and RHB-107 that has completed Phase II clinical trial for gastrointestinal and other solid tumors.
Featured Story: Price-Sales Ratio
Receive News & Ratings for REDHILL BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REDHILL BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.